Latest & greatest articles for metoprolol

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on metoprolol or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on metoprolol and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for metoprolol

1. Metoprolol

Metoprolol Top results for metoprolol - Trip Database or use your Google+ account Find evidence fast My query is: English Français Deutsch Čeština Español Magyar Svenska ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search (...) button. An example search might look like (#1 or #2) and (#3 or #4) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for metoprolol The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory

Trip Latest and Greatest2018

2. Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator

Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator 29699616 2018 04 27 1558-3597 71 17 2018 May 01 Journal of the American College of Cardiology J. Am. Coll. Cardiol. Propranolol Versus Metoprolol for Treatment of Electrical Storm in Patients With Implantable Cardioverter-Defibrillator. 1897-1906 S0735-1097(18)33497-1 10.1016/j.jacc.2018.02.056 Electrical storm (ES), characterized by unrelenting recurrences of ventricular (...) arrhythmias, is observed in approximately 30% of patients with implantable cardioverter-defibrillators (ICDs) and is associated with high mortality rates. Sympathetic blockade with β-blockers, usually in combination with intravenous (IV) amiodarone, have proved highly effective in the suppression of ES. In this study, we compared the efficacy of a nonselective β-blocker (propranolol) versus a β 1 -selective blocker (metoprolol) in the management of ES. Between 2011 and 2016, 60 ICD patients (45 men, mean

EvidenceUpdates2018

3. Metoprolol

Metoprolol USE OF METOPROLOL IN PREGNANCY 0344 892 0909 USE OF METOPROLOL IN PREGNANCY (Date of issue: March 2016 , Version: 2 ) This is a UKTIS monograph for use by health care professionals. For case-specific advice please contact UKTIS on 0344 892 0909. To report an exposure please download and complete a . Please encourage all women to complete an . Summary Metoprolol is a cardioselective (beta1 selective) beta-adrenoceptor blocking drug licensed for the treatment of hypertension, angina (...) pectoris, cardiac arrhythmias, myocardial infarction, adjunctive management of thyrotoxicosis, and prophylaxis of migraine. There are no published data on overall rates of congenital malformation following metoprolol use in pregnancy. A single case-control study found no association between first trimester metoprolol exposure and posterior cleft palate. A further case-control study found no association between gestational metoprolol use and hypospadias in male infants. Both findings require

UK Teratology Information Service2014

4. Comparison of Candesartan versus Metoprolol for treatment of systemic hypertension after repaired aortic coarctation

Comparison of Candesartan versus Metoprolol for treatment of systemic hypertension after repaired aortic coarctation 20102922 2010 01 27 2010 02 25 2013 11 21 1879-1913 105 2 2010 Jan 15 The American journal of cardiology Am. J. Cardiol. Comparison of Candesartan versus Metoprolol for treatment of systemic hypertension after repaired aortic coarctation. 217-22 10.1016/j.amjcard.2009.08.674 Even after successful repair, hypertension is one of the main determinants of cardiovascular morbidity (...) and mortality in patients with aortic coarctation (CoA). We compared the effect of candesartan (angiotensin II receptor blockade) and metoprolol (beta-adrenergic receptor blockade) on blood pressure, large artery stiffness, and neurohormonal status in hypertensive patients after repair of CoA. In the present open-label, crossover study, hypertensive patients after CoA repair were first randomly assigned to treatment with candesartan 8 mg or metoprolol 100 mg once per day. After 8 weeks of treatment with one

EvidenceUpdates2010

5. Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients

Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients 18564334 2009 02 13 2009 11 02 2013 11 21 1463-1326 11 3 2009 Mar Diabetes, obesity & metabolism Diabetes Obes Metab Comparison of carvedilol and metoprolol on serum lipid concentration in diabetic hypertensive patients. 234-8 10.1111/j.1463-1326.2008.00927.x Vasoconstricting beta-blocker use is associated with a reduction in HDL cholesterol, higher triglyceride, total cholesterol (...) and LDL cholesterol levels, whereas carvedilol, a vasodilating beta-blocker, has not been associated with these effects. To compare in a randomized, double-blind study, the effects of the beta 1-blocker metoprolol tartrate with the combined alpha 1, beta-blocker carvedilol on serum lipid concentrations. A prospective randomized, double-blind, parallel-group trial compared the effects of carvedilol and metoprolol on total cholesterol, triglycerides, calculated LDL, HDL and non-HDL cholesterol levels at baseline

EvidenceUpdates2009

6. Is Sotalol A Better Choice Over Metoprolol for Atrial Fibrillation Prophylaxis Post Coronary Artery Bypass Graft Surgery?

Is Sotalol A Better Choice Over Metoprolol for Atrial Fibrillation Prophylaxis Post Coronary Artery Bypass Graft Surgery? "Is Sotalol A Better Choice Over Metoprolol for Atrial Fibrillation Pro" by Felipson Ramos < > > > > > Title Author Date of Award 8-15-2009 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies First Advisor James Ferguson, PA-C Second Advisor Rob Rosenow PharmD, OD Third Advisor Annjanette Sommers MS, PA-C Rights . Abstract Background (...) : Atrial Fibrillation (AF) is the most common arrhythmia post Coronary Artery Bypass Graft surgery (CABG). Up to 50% of patients who undergo a CABG procedure will have AF. Metoprolol, a conventional beta-blocker, has been the drug of choice for AF prophylaxis. Sotalol, also a beta-blocker, with class III antiarrythmic effects, could possibly provide a better prophylaxis intervention of AF post CABG surgery. Methods: The focus of this study was to review clinical trials on the comparison between sotalol

Pacific University EBM Capstone Project2009

7. Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure

Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword (...) Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure Article Text Therapeutics Carvedilol was more effective than metoprolol for preventing cardiovascular events in heart failure Statistics from Altmetric.com No Altmetric data available for this article

Evidence-Based Medicine (Requires free registration)2008

8. Metoprolol prevented myocardial infarction but increased risk of stroke and death after non-cardiac surgery

Metoprolol prevented myocardial infarction but increased risk of stroke and death after non-cardiac surgery Metoprolol prevented myocardial infarction but increased risk of stroke and death after non-cardiac surgery | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Metoprolol prevented myocardial infarction but increased risk of stroke and death after non-cardiac surgery Article Text Therapeutics Metoprolol prevented myocardial infarction but increased risk of stroke and death after non-cardiac surgery Statistics from Altmetric.com No Altmetric data available

Evidence-Based Medicine (Requires free registration)2008

9. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial.

Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. 18479744 2008 06 02 2008 06 23 2015 11 19 1474-547X 371 9627 2008 May 31 Lancet (London, England) Lancet Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. 1839-47 10.1016/S0140-6736(08)60601-7 Trials of beta blockers in patients undergoing non-cardiac surgery have reported (...) conflicting results. This randomised controlled trial, done in 190 hospitals in 23 countries, was designed to investigate the effects of perioperative beta blockers. We randomly assigned 8351 patients with, or at risk of, atherosclerotic disease who were undergoing non-cardiac surgery to receive extended-release metoprolol succinate (n=4174) or placebo (n=4177), by a computerised randomisation phone service. Study treatment was started 2-4 h before surgery and continued for 30 days. Patients, health-care

Lancet2008

10. Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction

Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your (...) user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute myocardial infarction Article Text Therapeutics Addition of clopidogrel to aspirin, but not early use of metoprolol, improved overall outcome in acute

Evidence-Based Medicine (Requires free registration)2007

11. Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial

Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial Economic implications of extended-release metoprolol succinate for heart failure in the MERIT-HF trial: a US perspective of the MERIT-HF trial Caro J J, Migliaccio-Walle K, O'Brien J A, Nova W, Kim J, Hauch O (...) , Hillson E, Wedel H, Hjalmarson A, Gottlieb S, Deedwania P C, Wikstrand J Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The study examined once-daily extended-release (ER) metoprolol added to standard treatment for patients

NHS Economic Evaluation Database.2005

12. Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure

Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure | Evidence-Based Medicine This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search (...) for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure Article Text Therapeutics Carvedilol was more effective than metoprolol tartrate for lowering mortality in chronic heart failure Free Curt D Furberg , MD, PhD , Bruce M Psaty , MD, PhD Statistics

Evidence-Based Medicine (Requires free registration)2005

13. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial.

Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. 16271643 2005 11 07 2005 12 01 2015 06 16 1474-547X 366 9497 2005 Nov 05 Lancet (London, England) Lancet Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. 1622-32 Despite previous randomised trials of early beta-blocker therapy in the emergency treatment of myocardial infarction (MI (...) ), uncertainty has persisted about the value of adding it to current standard interventions (eg, aspirin and fibrinolytic therapy), and the balance of potential benefits and hazards is still unclear in high-risk patients. 45,852 patients admitted to 1250 hospitals within 24 h of suspected acute MI onset were randomly allocated metoprolol (up to 15 mg intravenous then 200 mg oral daily; n=22,929) or matching placebo (n=22,923). 93% had ST-segment elevation or bundle branch block, and 7% had ST-segment

Lancet2005

14. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial.

Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. 15536109 2004 11 10 2004 11 15 2016 10 17 1538-3598 292 18 2004 Nov 10 JAMA JAMA Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. 2227-36 Beta-blockers have been shown to decrease cardiovascular risk in patients with hypertension and type 2 diabetes mellitus (DM); however (...) , some components of the metabolic syndrome are worsened by some beta-blockers. To compare the effects of beta-blockers with different pharmacological profiles on glycemic and metabolic control in participants with DM and hypertension receiving renin-angiotensin system (RAS) blockade, in the context of cardiovascular risk factors. A randomized, double-blind, parallel-group trial (The Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives [GEMINI]) conducted between

JAMA2004

15. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial.

Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. 12853193 2003 07 10 2003 07 23 2016 08 03 1474-547X 362 9377 2003 Jul 05 Lancet (London, England) Lancet Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. 7-13 Beta (...) blockers reduce mortality in patients who have chronic heart failure, systolic dysfunction, and are on background treatment with diuretics and angiotensin-converting enzyme inhibitors. We aimed to compare the effects of carvedilol and metoprolol on clinical outcome. In a multicentre, double-blind, and randomised parallel group trial, we assigned 1511 patients with chronic heart failure to treatment with carvedilol (target dose 25 mg twice daily) and 1518 to metoprolol (metoprolol tartrate, target dose 50 mg

Lancet2003

16. Reimbursement claims analysis of outcomes with carvedilol and metoprolol

Reimbursement claims analysis of outcomes with carvedilol and metoprolol Reimbursement claims analysis of outcomes with carvedilol and metoprolol Reimbursement claims analysis of outcomes with carvedilol and metoprolol Luzier A B, Antell L A, Chang L L, Xuan J W, Roth D A Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed (...) critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of carvedilol and metoprolol, two beta-blockers, for the treatment of heart failure (HF). Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population The study population comprised patients with HF. The inclusion criteria specified patients aged between 18 and 64 years with the following: two in- or outpatient medical claims with HF (International

NHS Economic Evaluation Database.2002

17. Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group.

Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial in congestive heart failure (MERIT-HF). MERIT-HF Study Group. 10714728 2000 03 16 2000 03 16 2016 10 17 0098-7484 283 10 2000 Mar 08 JAMA JAMA Effects of controlled-release metoprolol on total mortality, hospitalizations, and well-being in patients with heart failure: the Metoprolol CR/XL Randomized Intervention Trial (...) in congestive heart failure (MERIT-HF). MERIT-HF Study Group. 1295-302 Results from recent studies on the effects of beta1-blockade in patients with heart failure demonstrated a 34% reduction in total mortality. However, the effect of beta1-blockade on the frequency of hospitalizations, symptoms, and quality of life in patients with heart failure has not been fully explored. To examine the effects of the beta1-blocker controlled-release/extended-release metoprolol succinate (metoprolol CR/XL) on mortality

JAMA2000

18. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)

Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) 10376614 1999 06 29 1999 06 29 2015 06 16 0140-6736 353 9169 1999 Jun 12 Lancet (London, England) Lancet Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) 2001-7 Metoprolol can improve haemodynamics in chronic heart failure, but survival benefit has not been proven. We (...) investigated whether metoprolol controlled release/extended release (CR/XL) once daily, in addition to standard therapy, would lower mortality in patients with decreased ejection fraction and symptoms of heart failure. We enrolled 3991 patients with chronic heart failure in New York Heart Association (NYHA) functional class II-IV and with ejection fraction of 0.40 or less, stabilised with optimum standard therapy, in a double-blind randomised controlled study. Randomisation was preceded by a 2-week single

Lancet1999

19. Double blind randomised controlled trial of effect of metoprolol on myocardial ischaemia during endoscopic cholangiopancreatography.

Double blind randomised controlled trial of effect of metoprolol on myocardial ischaemia during endoscopic cholangiopancreatography. 8704533 1996 09 10 1996 09 10 2013 11 21 0959-8138 313 7052 1996 Aug 03 BMJ (Clinical research ed.) BMJ Double blind randomised controlled trial of effect of metoprolol on myocardial ischaemia during endoscopic cholangiopancreatography. 258-61 To evaluate the effect of metoprolol, a beta adrenergic blocking drug, on the occurrence of myocardial ischaemia during (...) endoscopic cholangiopancreatography. Double blind, randomised, controlled trial. University Hospital. 38 (two groups of 19) patients scheduled for endoscopic cholangiopancreatography. Metoprolol 100 mg or placebo as premedication two hours before endoscopy. Heart rate, arterial oxygen saturation by continuous pulse oximetry, ST segment changes during endoscopic cholangiopancreatography (an ST segment deviation > 1 mV was defined as myocardial ischaemia), electrocardiogram monitored continuously

BMJ1996 Full Text: Link to full Text with Trip Pro

20. Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group.

Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. 7902479 1993 12 29 1993 12 29 2015 06 16 0140-6736 342 8885 1993 Dec 11 Lancet (London, England) Lancet Beneficial effects of metoprolol in idiopathic dilated cardiomyopathy. Metoprolol in Dilated Cardiomyopathy (MDC) Trial Study Group. 1441-6 Several small studies have suggested beneficial effects of long-term beta-blocker treatment in idiopathic dilated (...) cardiomyopathy. Our large multicentre study aimed to find out whether metoprolol improves overall survival and morbidity in this disorder. 383 subjects with heart failure from idiopathic dilated cardiomyopathy (ejection fraction < 0.40) were randomly assigned placebo or metoprolol. 94% were in New York Heart Association functional classes II and III, and 80% were receiving background treatment. A test dose of metoprolol (5 mg twice daily) was given for 2-7 days; those tolerating this dose (96%) entered

Lancet1993